Short Interest in Valneva SE (NASDAQ:VALN) Declines By 27.3%

Valneva SE (NASDAQ:VALN - Get Free Report) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 4,800 shares, a decrease of 27.3% from the April 30th total of 6,600 shares. Based on an average daily volume of 78,300 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC purchased a new position in shares of Valneva in the 1st quarter valued at approximately $94,000. ABC Arbitrage SA purchased a new position in shares of Valneva in the 4th quarter valued at approximately $84,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after purchasing an additional 30,859 shares during the period. Hedge funds and other institutional investors own 11.39% of the company's stock.

Valneva Trading Down 3.3%

Shares of VALN stock traded down $0.21 during trading hours on Tuesday, reaching $6.20. The company's stock had a trading volume of 5,315 shares, compared to its average volume of 42,435. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. Valneva has a one year low of $3.62 and a one year high of $9.16. The stock has a market capitalization of $518.54 million, a P/E ratio of -47.69 and a beta of 1.85. The firm's fifty day simple moving average is $6.55 and its 200 day simple moving average is $5.84.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.27. The business had revenue of $51.79 million for the quarter, compared to analysts' expectations of $41.80 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. Equities research analysts expect that Valneva will post 0.13 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Guggenheim reduced their price target on Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. HC Wainwright restated a "buy" rating and set a $17.00 price target on shares of Valneva in a research report on Tuesday, April 15th.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.